Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06722157 · ClinicalTrials.gov registry record · Phase 2
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
A Phase 2 study of Geographic Atrophy and Macular Degeneration, Age-related, sponsored by Boehringer Ingelheim.
- Active
- Registry status
- Phase 2
- Development phase
- 202
- Enrollment target
- 20
- Study locations
NCT06722157: Active Phase 2 study of Geographic Atrophy and Macular Degeneration, Age-related, sponsored by Boehringer Ingelheim.
NCT06722157 is a Phase 2 study of Geographic Atrophy and Macular Degeneration, Age-related that is active but no longer recruiting, run by Boehringer Ingelheim. The registered enrollment target is 202 participants, roughly in line with the 215-participant average among 27 other Geographic Atrophy trials with a reported enrollment target. The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06722157, a Phase 2 study of Geographic Atrophy and Macular Degeneration, Age-related, is active but no longer recruiting, sponsored by Boehringer Ingelheim.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 202 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine already used to treat people with geographic atrophy. In this study, participants receive either BI 771716 or pegcetacoplan as injections in the eye. Participants are in the study for a little longer than a year and visit the study site every 4 weeks. At the visits, the study doctor checks the eyes of the participants. The results are compared between the groups of participants to see whether the treatment works. The study doctor also regularly checks participants' health and takes note of any unwanted effects.
Conditions Studied
Interventions
- DRUG Pegcetacoplan
- DRUG BI 771716
- DRUG Sham comparator to BI 771716
Study Locations (20)
California
- Global Research Management - Glendale
- Retina Associates of Southern California - Huntington Beach
- Retinal Consultants Medical Group, Inc - Modesto
- Eye Research Foundation - Newport Beach
- Retina Consultants of San Diego - Poway
- Retinal Consultants Medical Group - Sacramento
- Bay Area Retina Associates - Walnut Creek - Walnut Creek
Arizona
- Associated Retina Consultants - Gilbert
- Associated Retina Consultants, Ltd. - Phoenix
- Phoenix Retina Associates - Phoenix
- Retina Macula Institute of Arizona - Scottsdale
Florida
- Rand Eye Institute - Deerfield Beach
- Retina Group of Florida - Fort Lauderdale
- Eye Associates of Pinellas - Pinellas Park
- Retina Vitreous Associates of Florida - St. Petersburg
Connecticut
- Connecticut Eye Consultants, PC - Danbury
- Retina Group of New England, PC - Waterford
Colorado
- Colorado Retina Associates - Lakewood
Georgia
- Southeast Retina Center, PC - Augusta
Illinois
- University Retina and Macula Associates - Lemont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2025-01-06 |
| Est. Completion | 2026-10-16 |
| Phase | Phase 2 |
What the registry record for NCT06722157 still lists
NCT06722157 is an interventional study that assigns participants to a tested intervention. The registered 202 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 215-participant average among 27 other Geographic Atrophy trials with a reported enrollment target.
The record links to 2 conditions, with Geographic Atrophy appearing as the primary indexed condition, and to 3 interventions - of which Pegcetacoplan is the first listed.
NCT06722157 names 20 study sites across 7 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT06722157 about?
NCT06722157 is a clinical study titled "A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy". This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan. BI 771716 is being developed to treat people with geographic atrophy. Pegcetacoplan is a medicine ...
What is the current status of trial NCT06722157?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 202 participants. The study started on 2025-01-06. Estimated completion is 2026-10-16.
What conditions does trial NCT06722157 study?
This clinical trial studies the following conditions: Geographic Atrophy, Macular Degeneration, Age-related.
What interventions are being tested in trial NCT06722157?
The interventions under investigation include: Pegcetacoplan (DRUG), BI 771716 (DRUG), Sham comparator to BI 771716 (DRUG).
Who is sponsoring clinical trial NCT06722157?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06722157 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06722157's enrollment target sits among peer trials
202 10th of 27 higher than 18 of 27 other Geographic Atrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Geographic Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
RECRUITING · Phase 2
-
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05272254 · 202 participants · Phase 2
Povidone Iodine Efficacy Study
- NCT05701280 · 202 participants · NA
Pilot/Pivotal Study of DBS+Rehab After Stroke
- NCT05932589 · 202 participants
Neurophysiologic Biomarkers in Rett Syndrome
- NCT06014931 · 202 participants · NA
Telehealth-enhanced Patient-oriented Recovery Trajectory After Intensive Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI